No Data
ST Tiansheng: 2024 Annual Results Forecast
Tiansheng Pharmaceutical Group (002872.SZ): Expected loss of 62 million yuan - 92.5 million yuan for the year 2024.
Gelonghui, January 20, ST Tiansheng (002872.SZ) announced the performance forecast for 2024. The net income attributable to shareholders of the listed company is expected to be a loss of 62 million yuan to 92.5 million yuan, compared to a loss of 93.0737 million yuan in the same period last year; the net income after deducting non-recurring gains and losses is expected to be a loss of 80 million yuan to 115 million yuan, compared to a loss of 103.1033 million yuan in the same period last year; the basic EPS is expected to be a loss of 0.1950 yuan/share to 0.2909 yuan/share; the revenue is expected to be 0.52 billion yuan to 0.61 billion yuan.
Tiansheng Pharmaceutical Group Co., Ltd. (SZSE:002872) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
On January 9, A-share investment warning: Tiansheng Pharmaceutical Group and its controlling shareholders and actual controllers have received a case notification letter from the Securities Regulatory Commission for suspected violations of information dis
Tiansheng Pharmaceutical Group and its controlling shareholders, as well as the actual controllers, have received a notice of investigation from the China Securities Regulatory Commission for suspected violations of information disclosure. Dalian Sunasia Tourism Holding's holding subsidiary and associated company's assets are being judicially auctioned. ST Lingda stated that the company's legal representative, subsidiaries, and legal representatives are restricted from consumption. Shenzhen Hopewind Electric indicated that there are no relevant Orders for Datacenter business, which does not involve Datacenter hotspots. Jiangsu Seagull Cooling Tower stated that Nuclear Power and Data Computing Center belong to the company's emerging business, currently accounting for less than 1% of revenue. *ST Aonong continues to be subjected to (Delisted) risk warnings and other risk warnings.
Tiansheng Pharmaceutical Group (002872.SZ): Plans to increase capital investment in Changsheng Pharmaceutical by 29.4 million yuan.
Gelonghui, on December 27, announced that Tiansheng Pharmaceutical Group (002872.SZ) disclosed that to meet the daily Operation development needs of Changsheng Pharmaceutical, the company and Chongqing Pharmaceutical intend to increase their capital in Changsheng Pharmaceutical in proportion to their shareholding. The company plans to increase its capital in Changsheng Pharmaceutical by 29.4 million yuan from its own funds, while Chongqing Pharmaceutical intends to increase its capital in Changsheng Pharmaceutical by 30.6 million yuan in cash. The total capital increase amounts to 60 million yuan, which will be included in the registered capital of Changsheng Pharmaceutical. After the completion of this capital increase, the registered capital of Changsheng Pharmaceutical will increase from 100.6 million yuan to 160.6 million yuan, and the company will still Hold 49% of the equity in Changsheng Pharmaceutical.
Tiansheng Pharmaceutical Group (002872.SZ): The subsidiary participates in the tenth batch of national Pharmaceutical centralized procurement and plans to be selected.
On December 13, Gelonghui reported that Tiansheng Pharmaceutical Group (002872.SZ) announced that its wholly-owned subsidiary Hubei Tiansheng Pharmaceutical Co., Ltd. participated in the bidding organized by the National Organization for Pharmaceutical Joint Procurement Office for the tenth batch of nationwide centralized pharmaceutical procurement. According to the "Proposed Selection Results Announcement for National Centralized Pharmaceutical Procurement" published by the Joint Procurement Office on December 12, 2024, Hubei Tiansheng's product, aminophylline injection, is proposed to win the bid for this centralized procurement.